Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ili-alone in advanced extremity melanoma

Joyce Wong, Y. Ann Chen, Kate J. Fisher, Georgia M. Beasley, Douglas Tyler, Jonathan S. Zager

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Isolated limb infusion (ILI) is a limb-preserving treatment for in-transit extremity melanoma. The benefit of resecting residual disease after ILI is unclear. Methods: A multi-institutional experience was analyzed comparing patients who underwent ILI plus resection of residual disease (ILI + RES) versus ILI-alone. Results: A total of 176 patients were included, 154 with ILI-alone and 22 with ILI + RES. There were no differences between the groups with respect to gender, age, extremity affected, or time from diagnosis to ILI. All surgical resections were performed as an outpatient procedure, separate from the ILI. Within the ILI + RES group, 15 (68 %) had a partial response (PR), 2 (9 %) stable disease (SD), and 5 (23 %) progressive disease (PD). The ILI-alone group had 52 (34 %) CR, 30 (19 %) PR, 15 (10 %) SD, and 46 (30 %) PD. Eleven (7 %) ILI-alone patients did not have 3-month response available for review. Evaluating overall survival (OS) from date of ILI, the ILI-alone group had a median OS of 30.9 months, whereas the ILI + RES group had not reached median OS, p = 0.304. Although the ILI + RES group had a slightly longer disease-free survival (DFS) compared to those with a CR after ILI-alone (12.4 vs. 9.6), this was not statistically significant, p = 0.978. Within the ILI + RES group, those with an initial PR after ILI had improved DFS versus those with SD or PD after ILI, p < 0.0001. Conclusions: Resection of residual disease after ILI offers a DFS and OS similar to those who have a CR after ILI-alone. It may offer a treatment strategy that benefits patients undergoing ILI.

Original languageEnglish (US)
Pages (from-to)650-655
Number of pages6
JournalAnnals of Surgical Oncology
Volume21
Issue number2
DOIs
StatePublished - Feb 2014
Externally publishedYes

Fingerprint

Melanoma
Extremities
Disease-Free Survival
Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ili-alone in advanced extremity melanoma. / Wong, Joyce; Ann Chen, Y.; Fisher, Kate J.; Beasley, Georgia M.; Tyler, Douglas; Zager, Jonathan S.

In: Annals of Surgical Oncology, Vol. 21, No. 2, 02.2014, p. 650-655.

Research output: Contribution to journalArticle

Wong, Joyce ; Ann Chen, Y. ; Fisher, Kate J. ; Beasley, Georgia M. ; Tyler, Douglas ; Zager, Jonathan S. / Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ili-alone in advanced extremity melanoma. In: Annals of Surgical Oncology. 2014 ; Vol. 21, No. 2. pp. 650-655.
@article{f50c46993a48433daec48df970544462,
title = "Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ili-alone in advanced extremity melanoma",
abstract = "Background: Isolated limb infusion (ILI) is a limb-preserving treatment for in-transit extremity melanoma. The benefit of resecting residual disease after ILI is unclear. Methods: A multi-institutional experience was analyzed comparing patients who underwent ILI plus resection of residual disease (ILI + RES) versus ILI-alone. Results: A total of 176 patients were included, 154 with ILI-alone and 22 with ILI + RES. There were no differences between the groups with respect to gender, age, extremity affected, or time from diagnosis to ILI. All surgical resections were performed as an outpatient procedure, separate from the ILI. Within the ILI + RES group, 15 (68 {\%}) had a partial response (PR), 2 (9 {\%}) stable disease (SD), and 5 (23 {\%}) progressive disease (PD). The ILI-alone group had 52 (34 {\%}) CR, 30 (19 {\%}) PR, 15 (10 {\%}) SD, and 46 (30 {\%}) PD. Eleven (7 {\%}) ILI-alone patients did not have 3-month response available for review. Evaluating overall survival (OS) from date of ILI, the ILI-alone group had a median OS of 30.9 months, whereas the ILI + RES group had not reached median OS, p = 0.304. Although the ILI + RES group had a slightly longer disease-free survival (DFS) compared to those with a CR after ILI-alone (12.4 vs. 9.6), this was not statistically significant, p = 0.978. Within the ILI + RES group, those with an initial PR after ILI had improved DFS versus those with SD or PD after ILI, p < 0.0001. Conclusions: Resection of residual disease after ILI offers a DFS and OS similar to those who have a CR after ILI-alone. It may offer a treatment strategy that benefits patients undergoing ILI.",
author = "Joyce Wong and {Ann Chen}, Y. and Fisher, {Kate J.} and Beasley, {Georgia M.} and Douglas Tyler and Zager, {Jonathan S.}",
year = "2014",
month = "2",
doi = "10.1245/s10434-013-3336-4",
language = "English (US)",
volume = "21",
pages = "650--655",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ili-alone in advanced extremity melanoma

AU - Wong, Joyce

AU - Ann Chen, Y.

AU - Fisher, Kate J.

AU - Beasley, Georgia M.

AU - Tyler, Douglas

AU - Zager, Jonathan S.

PY - 2014/2

Y1 - 2014/2

N2 - Background: Isolated limb infusion (ILI) is a limb-preserving treatment for in-transit extremity melanoma. The benefit of resecting residual disease after ILI is unclear. Methods: A multi-institutional experience was analyzed comparing patients who underwent ILI plus resection of residual disease (ILI + RES) versus ILI-alone. Results: A total of 176 patients were included, 154 with ILI-alone and 22 with ILI + RES. There were no differences between the groups with respect to gender, age, extremity affected, or time from diagnosis to ILI. All surgical resections were performed as an outpatient procedure, separate from the ILI. Within the ILI + RES group, 15 (68 %) had a partial response (PR), 2 (9 %) stable disease (SD), and 5 (23 %) progressive disease (PD). The ILI-alone group had 52 (34 %) CR, 30 (19 %) PR, 15 (10 %) SD, and 46 (30 %) PD. Eleven (7 %) ILI-alone patients did not have 3-month response available for review. Evaluating overall survival (OS) from date of ILI, the ILI-alone group had a median OS of 30.9 months, whereas the ILI + RES group had not reached median OS, p = 0.304. Although the ILI + RES group had a slightly longer disease-free survival (DFS) compared to those with a CR after ILI-alone (12.4 vs. 9.6), this was not statistically significant, p = 0.978. Within the ILI + RES group, those with an initial PR after ILI had improved DFS versus those with SD or PD after ILI, p < 0.0001. Conclusions: Resection of residual disease after ILI offers a DFS and OS similar to those who have a CR after ILI-alone. It may offer a treatment strategy that benefits patients undergoing ILI.

AB - Background: Isolated limb infusion (ILI) is a limb-preserving treatment for in-transit extremity melanoma. The benefit of resecting residual disease after ILI is unclear. Methods: A multi-institutional experience was analyzed comparing patients who underwent ILI plus resection of residual disease (ILI + RES) versus ILI-alone. Results: A total of 176 patients were included, 154 with ILI-alone and 22 with ILI + RES. There were no differences between the groups with respect to gender, age, extremity affected, or time from diagnosis to ILI. All surgical resections were performed as an outpatient procedure, separate from the ILI. Within the ILI + RES group, 15 (68 %) had a partial response (PR), 2 (9 %) stable disease (SD), and 5 (23 %) progressive disease (PD). The ILI-alone group had 52 (34 %) CR, 30 (19 %) PR, 15 (10 %) SD, and 46 (30 %) PD. Eleven (7 %) ILI-alone patients did not have 3-month response available for review. Evaluating overall survival (OS) from date of ILI, the ILI-alone group had a median OS of 30.9 months, whereas the ILI + RES group had not reached median OS, p = 0.304. Although the ILI + RES group had a slightly longer disease-free survival (DFS) compared to those with a CR after ILI-alone (12.4 vs. 9.6), this was not statistically significant, p = 0.978. Within the ILI + RES group, those with an initial PR after ILI had improved DFS versus those with SD or PD after ILI, p < 0.0001. Conclusions: Resection of residual disease after ILI offers a DFS and OS similar to those who have a CR after ILI-alone. It may offer a treatment strategy that benefits patients undergoing ILI.

UR - http://www.scopus.com/inward/record.url?scp=84896721839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896721839&partnerID=8YFLogxK

U2 - 10.1245/s10434-013-3336-4

DO - 10.1245/s10434-013-3336-4

M3 - Article

C2 - 24162840

AN - SCOPUS:84896721839

VL - 21

SP - 650

EP - 655

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 2

ER -